This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease | MicrobiomeTrials
← Back to trials NCT07564505
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease Recruiting PHASE4 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-08-13Est. Completion: 2029-03
Enrollment target: 30 participantsLocations Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China Other microbiome trials you might be interested in Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) Inflamatory Bowel Disease
Pediatric inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic condition ass…
Madrid, Spain Est. completion Nov 1, 2026
Inflammatory Bowel Diseases
The purpose of this study is to evaluate whether trough serum infliximab concentrations at the time of loss of clinical …
Phoenix, United States Completed Jul 2019